New data show the LP.8.1-adapted COVID-19 vaccine generates ≥4-fold antibody increases in older and high-risk adults, with no new safety concerns.

Zilebesiran’s twice-yearly dosing and sustained BP reductions could offer a new therapeutic approach for adults with resistant hypertension and high CV risk who are uncontrolled on current SOC regimens.

Your daily dose of the clinical news you may have missed.

Family physician Teresa Lovins, MD, explains how primary care clinicians can determine when to manage depression and when urgent referral is needed.

Michael Crotty, MD, provides practical guidance for on integrating GLP-1 receptor agonists into a comprehensive obesity treatment plan.

Teresa Lovins, MD, describes the PHQ-9, GAD-7, and other brief screeners that help family physicians identify depression, anxiety, ADHD, and bipolar disorder in everyday practice.

Analysis presented at AHA Hypertension 2025 showed fewer than 6% of US adults use salt substitutes, despite their potential to improve BP control.

Your daily dose of the clinical news you may have missed.

This week’s podcast covers psoriasis trial results, intranasal insulin, COVID-19 booster safety, GLP-1 use in diabetes, and RSV vaccine uptake.

A secondary analysis of the DANFLU-2 trial found adults ≥65 receiving a high-dose flu vaccine had a 46% lower risk of myocarditis or pericarditis compared with standard-dose vaccination.